VivoSeq
Neurology

Parkinson's Disease (PD)

2

Pipeline Programs↗

12

Active Trials↗

13

Companies Involved↗

Parkinson's Disease (PD) is an early-stage landscape with 2 programs across 13 companies. The most active players are Eli Lilly, BlueRock Therapeutics, Boehringer Ingelheim. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

30/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2B

BlueRock Therapeutics

1 program

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalLundbeck logo

Lundbeck

0 programs

PreclinicalUCB logo

UCB

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

[18f]mk-0947

Invicro

Phase 2
No programs
Phase 31

Bemdaneprocel

BlueRock Therapeutics

Approved
No programs

Analysis

Trial Status

47

clinical trials

Completed30 · 64%
Recruiting5 · 11%
Not yet recruiting5 · 11%
Terminated4 · 9%
Active, not recruiting2 · 4%
Unknown status1 · 2%

Clinical Trials

Trial Activity

47 trials

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
Recruiting·Regeneron logoRegeneron·Phase 1·NCT07216066·46 enrolled
Moving Yourself in Space and Time Identifying Spatial and Temporal Components of Complex Rhythmic Movement Training for People With Parkinson's Disease and Cognitive Impairment
Recruiting·EEmory University·Preclinical·NCT07697664·210 enrolled
exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease
Recruiting·BBlueRock Therapeutics·Phase 3·NCT06944522·102 enrolled
Investigating the Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease
Recruiting·SSaglik Bilimleri Universitesi·Preclinical·NCT07641556·40 enrolled
An Open-label Study to Evaluate Brain α-Synuclein Deposition Using Positron Emission Tomography (PET) and [18F]MK-0947 in Patients With Parkinson's Disease
Recruiting·IInvicro·Phase 1·NCT07348250·22 enrolled
Tocotrienols in Parkinson's Disease (PD)
Active, not recruiting·NNational Neuroscience Institute·Phase 2·NCT04491383·100 enrolled
IMPACT 360 Study for Parkinson's Disease
Active, not recruiting·UUniversity of British Columbia·Phase 2·NCT07443293·60 enrolled
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Not yet recruiting·AAppello Pharmaceuticals, Inc.·Phase 2·NCT07432958·150 enrolled
Coordinated Reset Deep Brain Stimulation for Parkinson's Disease
Not yet recruiting·UUniversity of Minnesota·Phase 1·NCT07340073·24 enrolled
LRRK2 Associated Parkinson's Disease: Definition of a Clinical, Molecular and Neurophysiological Fingerprint
Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Preclinical·NCT07681219·20 enrolled
A Prospective, Single-Arm, Single-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Administration of LY-N001 Injection in Subjects With Moderate to Advanced Parkinson's Disease Carrying GBA1 Mutations
Not yet recruiting·LLingyi Biotech Co., Ltd.·Phase 1·NCT07685444·18 enrolled
A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's Disease
Not yet recruiting·EEnergenesis Biomedical Co., Ltd.·Phase 2·NCT07647614·105 enrolled
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT00297778·296 enrolled
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
Completed·UCB logoUCB·Phase 3·NCT00522379·514 enrolled
Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)
Completed·GSK logoGSK·Phase 2·NCT00434304·62 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)